+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Central Nervous System Drugs Market Research Reports

GABA Receptor Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

GABA Receptor Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Alpha-2 Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Alpha-2 Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Leukotriene D4 Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Leukotriene D4 Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Alpha-1 Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Alpha-1 Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Alpha-1 Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Alpha-1 Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Alpha v Beta 3 Integrin Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Alpha v Beta 3 Integrin Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Alpha v Beta 3/5/6 Integrin Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Alpha v Beta 3/5/6 Integrin Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Kainate Receptor Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Kainate Receptor Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
5-HT2C Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

5-HT2C Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
5-HT1A Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

5-HT1A Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
5-HT2A Agonists - Pipeline Insight, 2024 - Product Thumbnail Image

5-HT2A Agonists - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
D3 Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

D3 Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Neurokinin 1 (NK1) Receptor Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Neurokinin 1 (NK1) Receptor Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Kappa Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Kappa Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
From
Alpha-1A Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Alpha-1A Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Glutamate Receptor Antagonists - Pipeline Insight, 2024 - Product Thumbnail Image

Glutamate Receptor Antagonists - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
D1 Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

D1 Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Neurokinin (NK) Receptor Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Neurokinin (NK) Receptor Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Glucagon-Like Peptide (GLP) Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Glucagon-Like Peptide (GLP) Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 90 Pages
  • Global
From
Loading Indicator

The Central Nervous System Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs that target the central nervous system. These drugs are used to treat a variety of conditions, including neurological disorders, mental health issues, and pain management. The market is composed of a variety of companies, ranging from large multinationals to small start-ups. The Central Nervous System Drugs market is highly competitive, with companies competing to develop the most effective and safe treatments. Companies in the market are constantly researching and developing new drugs, as well as improving existing treatments. Many of these companies are also involved in clinical trials to test the safety and efficacy of their products. Some of the major companies in the Central Nervous System Drugs market include Pfizer, GlaxoSmithKline, Merck, Novartis, and Johnson & Johnson. These companies are involved in the development and production of a wide range of CNS drugs, including antidepressants, antipsychotics, and anticonvulsants. Show Less Read more